Nootropic Research Market

DSIP

A peptide discussed for sleep-related and neuroregulatory interest, though its evidence base is far less concrete than vendor listings suggest.

SleepNeuropeptideResearch Market

Also referenced as: Delta Sleep-Inducing Peptide

Price compare
77 tracked offers across 77 vendors · 14 dosages
Best trust-adjusted value: Puratek Peptides · Moderate trust · $2.41/mg
From
$2.41/mg
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Category
Nootropic

This profile is grouped by its dominant research and market lane, not by vendor shelf placement.

Aliases
1

Delta Sleep-Inducing Peptide

Signal depth
Low

No FDA label signal · 0 trials · 462 PubMed results

Preclinical
Research evidence

Current evidence for DSIP is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

DSIP has no clinical trials that name it and 462 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data
Lab / animal only
Trial quality
No human trials
Outcomes
No human trials
Replication
Multiple papers
Literature
Top-tier journals
The Lancet · 111 citations ALUMINIUM INCREASES PERMEABILITY OF THE BLOOD-BRAIN BARRIER TO LABELLED DSIP AND β-ENDORPHIN: POSSIBLE IMPLICATIONS FOR SENILE AND DIALYSIS DEMENTIA Peptides · 100 citations Delta-sleep-inducing peptide (DSIP): An update Neuroscience & Biobehavioral Reviews · 86 citations Delta-sleep-inducing peptide (DSIP): A review Journal Article Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal Article Domain-specific information preservation for Alzheimer's disease diagnosis with incomplete multi-modality neuroimages. Journal Article Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What DSIP is

DSIP stands for delta sleep-inducing peptide. It has been part of peptide and nootropic discussions for years, usually framed around sleep quality, stress, or neuroregulatory effects.

Why it matters

It is a good example of a compound with strong market persistence despite limited mainstream clinical presence. That makes it useful for understanding how peptide demand and evidence often move at different speeds.

Regulatory context

DSIP is not an FDA-approved sleep medicine in the United States. It should be treated as a research-market entry.

Practical reading note

This is one of the categories where vendor popularity can easily outrun evidence clarity, so careful skepticism is warranted.